PARP Inhibition in Cancer: An Update on Clinical Development
Year: 2019
Type: review
Source: Targeted Oncology
Institution: Cedars-Sinai Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: PARP inhibitors, synthetic lethality, DNA repair deficiency, BRCA mutations, homologous recombination deficiency, olaparib, niraparib, rucaparib, talazoparib, high-grade serous ovarian cancer, metastatic breast cancer, combination therapy, immunotherapy, drug resistance, clinical trial landscape
Open Access status: closed
OpenAlex ID: W2981233955
